Warning letter
Curtis Jacquot dba Pacific BioLogic Co.: warning letter of Dec 21, 2023
FDA warning letter 664804 · Division of Human and Animal Food Operations West V
Key facts
| Reference number | 664804 |
|---|---|
| Company | Curtis Jacquot dba Pacific BioLogic Co. |
| Subject | CGMP/Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements/Adulterated |
| Issue date | Dec 21, 2023 |
| Posted date | Feb 13, 2024 |
| Issuing office | Division of Human and Animal Food Operations West V |
| Product type | Food/Cosmetics |
| CFR sections cited | 111.75(a)(1)(i), 101.36, 111, 111.70, 111.73, 111.75, 111.95, 111.105, 111.210, 101.4(h)(1), 101.36(e)(1), 101.93(b) and 32 more |
| Inspection city | Concord |
| Inspection ZIP | 94521 |
| Inspection start date | Jun 1, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: